Search Results

A shedding analysis after AAV8 CNS injection revealed fragmented viral DNA without evidence of functional AAV particles in mice.

• Authors : Krause F; Department of Behavioral Neuroscience, ND7/31, Ruhr-University Bochum, Universitaetsstr. 150, D-44780, Bochum, Germany.; Schmidtke K

Subjects: Dependovirus*/Dependovirus*/Dependovirus*/genetics ; Genetic Vectors*/Genetic Vectors*/Genetic Vectors*/genetics ; Genetic Vectors*/Genetic Vectors*/Genetic Vectors*/administration & dosage

• Source: Gene therapy [Gene Ther] 2024 May; Vol. 31 (5-6), pp. 345-351. Date of Electronic Publication: 2024 Mar 12.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 9421525 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Mifepristone increases gamma-retroviral infection efficiency by enhancing the integration of virus into the genome of infected cells.

• Authors : Solodushko, V.; Fouty, B.

Subjects: RETROVIRUS diseases; GENES; CELLS

• Source: Gene Therapy; Oct2010, Vol. 17 Issue 10, p1253-1261, 9p, 7 Graphs

Record details

High throughput method for creating and screening recombinant adenoviruses.

• Authors : Davis, A R; Meyers, K; Wilson, J M

Subjects: GENE transfection; GREEN fluorescent protein; RECOMBINANT viruses

• Source: Gene Therapy; Aug98, Vol. 5 Issue 8, p1148, 5p

Record details

SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors.

• Authors : Berger, G.; Goujon, C.; Darlix, J.-L.

Subjects: GENE therapy; DNA synthesis; VIRUS diseases

• Source: Gene Therapy; Jan2009, Vol. 16 Issue 1, p159-163, 5p, 3 Graphs

Record details

A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.

• Authors : Fu, X.; Meng, F.; Tao, L.

Subjects: HERPES simplex virus; TUMORS

• Source: Gene Therapy; Aug2003, Vol. 10 Issue 17, p1458, 7p

Record details

Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL

• Authors : Lyon, A. R.; Babalis, D.; Morley-Smith, A. C.

• Source: Gene Therapy; December 2020, Vol. 27 Issue: 12 p579-590, 12p

Record details

Lentiviral gene transfer to reduce atherosclerosis progression by long-term CC-chemokine inhibition.

• Authors : Bursill, C. A.; McNeill, E.; Wang, L.

Subjects: CHEMOKINES; ATHEROSCLEROSIS; GENE therapy

• Source: Gene Therapy; Jan2009, Vol. 16 Issue 1, p93-102, 10p, 2 Diagrams, 1 Chart, 4 Graphs

Record details

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas.

• Authors : Galanis, E.; Okuno, S. H.; Nascimento, A. G.

Subjects: DRUG therapy; ADENOVIRUSES; THERAPEUTICS

• Source: Gene Therapy; Mar2005, Vol. 12 Issue 5, p437-445, 9p

Record details

Coimmunisation with type I IFN genes enhances protective immunity against cytomegalovirus and myocarditis in gB DNA-vaccinated mice.

• Authors : Cull, V.S.; Broomfield, S.; Bartlett, E.J.

Subjects: DNA vaccines; CYTOMEGALOVIRUS diseases; MYOCARDITIS

• Source: Gene Therapy; 10/15/2002, Vol. 9 Issue 20, p1369, 10p

Record details

Replication and packaging of helper-dependent adenoviral vectors.

• Authors : Sato, M.; Suzuki, S.; Kubo, S.

Subjects: GENETIC vectors; ADENOVIRUSES

• Source: Gene Therapy; 4/1/2002, Vol. 9 Issue 7, p472, 5p

Record details